Theravance Biopharma (TBPH) announced completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study in patients with symptomatic neurogenic orthostatic hypotension due to multiple system atrophy, a rare and progressive neurodegenerative disorder. nOH is a devastating condition affecting approximately 80% of MSA patients and is characterized by sudden drops in blood pressure upon standing, leading to symptoms such as dizziness, fainting, and blurry vision.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- Theravance Biopharma Settles Patent Dispute with Cipla
- Theravance Biopharma: Strong Product Performance and Promising Growth Prospects Justify Buy Rating
- Theravance Biopharma’s Earnings Call Highlights Strategic Gains
- Theravance Biopharma’s Strong Growth Potential Backed by Yupelri Success and Pipeline Advancements
- Theravance Biopharma Reports Strong Q2 2025 Results